Adaptive Biotechnologies (ADPT) Research & Development (2018 - 2026)

Adaptive Biotechnologies has disclosed Research & Development across 9 years of filings, most recently posting $26.4 million for Q2 2026.

• In Q2 2026, Research & Development rose 9.45% year-over-year to $26.4 million; the TTM figure through Jun 2026 stood at $99.0 million (up 3.45% YoY), while the FY2025 annual figure was $94.6 million, down 8.14% from the prior year.
• Research & Development came in at $26.4 million for Q2 2026 at Adaptive Biotechnologies, roughly flat from $26.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $37.8 million in Q1 2022 to a low of $22.6 million in Q4 2025.
• Average Research & Development over 5 years is $28.6 million, with a median of $27.5 million recorded in 2023.
• Year-over-year, Research & Development advanced 12.04% in 2022 and declined 21.35% in 2024.
• Over 5 years, Research & Development stood at $31.2 million in 2022, then slipped by 7.93% to $28.7 million in 2023, then dropped by 19.32% to $23.2 million in 2024, then decreased by 2.7% to $22.6 million in 2025, then increased by 17.06% to $26.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $26.4 million in Q2 2026, $26.3 million in Q1 2026, and $22.6 million in Q4 2025.